DE602006010428D1 - Chemisches verfahren - Google Patents

Chemisches verfahren

Info

Publication number
DE602006010428D1
DE602006010428D1 DE602006010428T DE602006010428T DE602006010428D1 DE 602006010428 D1 DE602006010428 D1 DE 602006010428D1 DE 602006010428 T DE602006010428 T DE 602006010428T DE 602006010428 T DE602006010428 T DE 602006010428T DE 602006010428 D1 DE602006010428 D1 DE 602006010428D1
Authority
DE
Germany
Prior art keywords
chemical process
chemical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006010428T
Other languages
English (en)
Inventor
Joergen Blixt
Michael David Golden
Philip John Hogan
David Michael Martin
Francis Joseph Montgomery
Zakariya Patel
John David Pittam
George Joseph Sependa
Christopher John Squire
Nicholas Cartwright Wright
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35395001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602006010428(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of DE602006010428D1 publication Critical patent/DE602006010428D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE602006010428T 2005-09-30 2006-09-27 Chemisches verfahren Active DE602006010428D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0519879.1A GB0519879D0 (en) 2005-09-30 2005-09-30 Chemical process
PCT/GB2006/003587 WO2007036713A2 (en) 2005-09-30 2006-09-27 Chemical process

Publications (1)

Publication Number Publication Date
DE602006010428D1 true DE602006010428D1 (de) 2009-12-24

Family

ID=35395001

Family Applications (2)

Application Number Title Priority Date Filing Date
DE602006017004T Active DE602006017004D1 (de) 2005-09-30 2006-09-27 Verfahren zur in-Situ chemischer Sulfonierung
DE602006010428T Active DE602006010428D1 (de) 2005-09-30 2006-09-27 Chemisches verfahren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE602006017004T Active DE602006017004D1 (de) 2005-09-30 2006-09-27 Verfahren zur in-Situ chemischer Sulfonierung

Country Status (32)

Country Link
US (8) US8163926B2 (de)
EP (2) EP1943240B1 (de)
JP (2) JP5213715B2 (de)
KR (1) KR101307641B1 (de)
CN (3) CN101277948B (de)
AR (1) AR055671A1 (de)
AT (2) ATE448218T1 (de)
AU (1) AU2006296367B2 (de)
BR (1) BRPI0616715A2 (de)
CA (2) CA2745829C (de)
CY (2) CY1110275T1 (de)
DE (2) DE602006017004D1 (de)
DK (2) DK1943240T3 (de)
ES (2) ES2335435T3 (de)
GB (1) GB0519879D0 (de)
HK (2) HK1122553A1 (de)
HR (2) HRP20100019T1 (de)
IL (2) IL190172A (de)
ME (2) ME01531B (de)
MY (2) MY149834A (de)
NO (1) NO342152B1 (de)
NZ (2) NZ566566A (de)
PL (2) PL1943240T3 (de)
PT (2) PT2053048E (de)
RS (2) RS51263B (de)
RU (1) RU2448102C2 (de)
SG (1) SG165416A1 (de)
SI (2) SI1943240T1 (de)
TW (2) TWI424991B (de)
UY (1) UY29824A1 (de)
WO (1) WO2007036713A2 (de)
ZA (1) ZA200802416B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2362774C1 (ru) * 2002-02-01 2009-07-27 Астразенека Аб Хиназолиновые соединения
GB0519879D0 (en) * 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
CL2007003158A1 (es) * 2006-11-02 2008-05-16 Astrazeneca Ab Procedimiento de preparacion de compuestos derivados de quinazolina o sus sales farmaceuticamente aceptables; compuestos intermediarios; procedimiento de preparacion.
EP2404595B1 (de) * 2011-09-01 2015-08-05 Symrise AG Verfahren zur Herstellung von Indanon-Derivaten
BR112015003101B1 (pt) * 2012-08-15 2022-06-14 Glaxo Group Limited Processo para a preparação de um composto
CN104098544A (zh) * 2013-04-07 2014-10-15 浙江九洲药物科技有限公司 一种凡德他尼的制备方法
CN106397401B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种抗癌药物的晶体化合物及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870083A (en) * 1987-11-24 1989-09-26 Merrell Dow Pharmaceuticals Inc. 1,4-Disubstituted-piperidinyl compounds useful as analgesics and muscle relaxants
JP2829744B2 (ja) 1989-05-31 1998-12-02 川研ファインケミカル株式会社 ピペリジンカルボン酸類の製造方法
WO1992006086A1 (en) 1990-10-01 1992-04-16 Janssen Pharmaceutica N.V. Novel 4-piperidinylcarbonyl derivatives
EP0646115B1 (de) 1991-03-28 2003-01-22 Eisai Co., Ltd. Neue heterocyclische/cyclische amine
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
AU658646B2 (en) 1991-05-10 1995-04-27 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
EP0638567A4 (de) 1993-02-18 1995-05-10 Kyowa Hakko Kogyo Kk Adenosin-aufnahme inhibitoren.
TW248554B (de) 1993-05-26 1995-06-01 Syntex Inc
DE4326344A1 (de) 1993-08-05 1995-02-09 Thomae Gmbh Dr K Carbonamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
EP0739336B1 (de) 1994-01-13 1998-08-26 MERCK SHARP & DOHME LTD. Gem-bissubstituierte azazyclische tachykinin-antagonisten
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
CA2265630A1 (en) 1996-09-13 1998-03-19 Gerald Mcmahon Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
UA72946C2 (uk) * 1999-11-05 2005-05-16 Астразенека Аб Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf)
GB0126879D0 (en) 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
DK1467995T3 (da) 2001-12-20 2010-09-20 Osi Pharm Inc Pyrrolopyrimidin-A2b-selektive antagonistforbindelser, deres syntese og anvendelse
RU2362774C1 (ru) 2002-02-01 2009-07-27 Астразенека Аб Хиназолиновые соединения
AU2003207291A1 (en) 2002-02-06 2003-09-02 Ube Industries, Ltd. Process for producing 4-aminoquinazoline compound
GB0218526D0 (en) 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
JP2006502132A (ja) 2002-08-09 2006-01-19 アストラゼネカ アクチボラグ 癌の治療における血管内皮細胞増殖因子受容体の阻害薬ｚｄ６４７４と放射線療法との併用
GB0223380D0 (en) 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
NZ541297A (en) 2003-02-13 2008-03-28 Astrazeneca Ab Combination therapy of ZD6474 with 5-FU or/and CPT-11
KR20120093411A (ko) 2003-07-10 2012-08-22 아스트라제네카 아베 백금 화합물 및 임의적으로 이온화 방사능과 조합된 퀴나졸린 유도체 ｚｄ6474의 혈관신생 및/또는 증가된 혈관 투과성 관련 질환 치료 용도
GB0318423D0 (en) 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
GB0519879D0 (en) * 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process

Also Published As

Publication number Publication date
PL1943240T3 (pl) 2010-04-30
GB0519879D0 (en) 2005-11-09
TWI424991B (zh) 2014-02-01
PL2053048T3 (pl) 2011-03-31
RU2448102C2 (ru) 2012-04-20
US20240150317A1 (en) 2024-05-09
CN102503898B (zh) 2015-03-25
CN102503933A (zh) 2012-06-20
RU2008116573A (ru) 2009-11-10
HRP20100019T1 (hr) 2010-02-28
NO342152B1 (no) 2018-04-03
NZ593930A (en) 2013-02-22
US20140378684A1 (en) 2014-12-25
CN102503933B (zh) 2014-06-25
TWI328580B (en) 2010-08-11
US20160185754A1 (en) 2016-06-30
US20090203905A1 (en) 2009-08-13
JP2009510039A (ja) 2009-03-12
US20180118716A1 (en) 2018-05-03
ES2350513T3 (es) 2011-01-24
SI2053048T1 (sl) 2010-12-31
EP2053048B8 (de) 2011-09-21
MY145540A (en) 2012-02-29
US8865899B2 (en) 2014-10-21
CA2624045A1 (en) 2007-04-05
DE602006017004D1 (de) 2010-10-28
US20120095229A1 (en) 2012-04-19
IL227574A (en) 2015-08-31
IL190172A0 (en) 2008-08-07
US20220033377A1 (en) 2022-02-03
ES2335435T3 (es) 2010-03-26
JP5654546B2 (ja) 2015-01-14
TW201018660A (en) 2010-05-16
AU2006296367A1 (en) 2007-04-05
DK1943240T3 (da) 2010-03-01
CY1110275T1 (el) 2015-01-14
MY149834A (en) 2013-10-31
KR20080049114A (ko) 2008-06-03
ME01531B (me) 2014-04-20
IL190172A (en) 2014-05-28
EP2053048A1 (de) 2009-04-29
JP2013063998A (ja) 2013-04-11
AU2006296367B2 (en) 2011-08-11
CN102503898A (zh) 2012-06-20
EP2053048B1 (de) 2010-09-15
NZ566566A (en) 2011-08-26
BRPI0616715A2 (pt) 2011-06-28
WO2007036713A3 (en) 2007-06-14
HK1130478A1 (en) 2009-12-31
JP5213715B2 (ja) 2013-06-19
US10344015B2 (en) 2019-07-09
WO2007036713A2 (en) 2007-04-05
UY29824A1 (es) 2007-04-30
HRP20100620T1 (hr) 2010-12-31
PT2053048E (pt) 2010-11-10
PT1943240E (pt) 2010-01-11
CA2745829C (en) 2013-07-02
EP1943240A2 (de) 2008-07-16
EP1943240B1 (de) 2009-11-11
SI1943240T1 (sl) 2010-02-26
CY1110887T1 (el) 2015-06-10
DK2053048T3 (da) 2010-11-29
ME01466B (me) 2014-04-20
RS51515B (en) 2011-06-30
CA2624045C (en) 2012-05-22
US20190263782A1 (en) 2019-08-29
CA2745829A1 (en) 2007-04-05
NO20081267L (no) 2008-04-30
CN101277948A (zh) 2008-10-01
ATE481399T1 (de) 2010-10-15
HK1122553A1 (en) 2009-05-22
SG165416A1 (en) 2010-10-28
ZA200802416B (en) 2009-01-28
KR101307641B1 (ko) 2013-09-12
TW200745036A (en) 2007-12-16
RS51263B (sr) 2010-12-31
US9815816B2 (en) 2017-11-14
ATE448218T1 (de) 2009-11-15
US8163926B2 (en) 2012-04-24
AR055671A1 (es) 2007-08-29
CN101277948B (zh) 2013-03-13

Similar Documents

Publication Publication Date Title
FI20060288A0 (fi) Pinnoitusmenetelmä
DK2089364T3 (da) Pyridinonforbindelser
BRPI0714512A2 (pt) Compostos químicos
DK1860941T3 (da) Biphenyl-N-(4-pyridyl)methylsufonamider
DE602007013995D1 (de) Beschichtungsverfahren
ATE442898T1 (de) Filtrationsverfahren
BRPI0718440A2 (pt) Processo de preparo de halogenetos de n-alquinaltrexona
DE602006002419D1 (de) Eintauchverfahren
DE602005006185D1 (de) Entwicklungsverfahren
DE602005019778D1 (de) Chemisches verfahren und produktionseinheit
BRPI0618203A2 (pt) aparelho de revestimento
DE602006009980D1 (de) Biosensor
DE602007013849D1 (de) Mikroreaktor
FI20065363A0 (fi) Erotusmenetelmä
DE602006012689D1 (de) Überprüfungsverfahren
ATE448218T1 (de) Chemisches verfahren
DK2014815T3 (da) Vaskeapparatur
DK1955066T3 (da) Membran-assay-fremgangsmåde
DE602006004709D1 (de) Beschichtungsverfahren
FI20050681A0 (fi) Paikoitusmenetelmä
DK1962960T3 (da) Fremgangsmåde til mikornisering
DE602007012645D1 (de) Elementmontageverfahren
NO20055841D0 (no) Kjemiske forbindelser
DK1934388T3 (da) Fremgangsmåde til lægemiddeludvikling
BRPI0610575A2 (pt) processo

Legal Events

Date Code Title Description
8364 No opposition during term of opposition